RxDoctor Payments Data

Paul Lee

Physician Assistant · Downey, CANPI 1144996745

Payments from drug & device makers

$3,800in general payments, 2019–2025

Across 125 payments — averaging $30.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$922
  • Sumitomo Pharma America, Inc.$467
  • AbbVie$407
  • Axonics, Inc.$303
  • Astellas Pharma US Inc$300
  • Pfizer$284
  • plus $1K from 16 others

What the payments were for

  • Travel & lodging$3379%
  • Food & beverage$3,16383%
  • Education$3018%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,800 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$15,265
Medicare patients
98
Services billed
858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix74$192,756
GemtesaVibegron109$92,850
MyrbetriqMirabegron76$68,521
Tolterodine Tartrate ErTolterodine Tartrate51$12,891
Tamsulosin Hcl575$8,413
Finasteride543$6,561
Oxybutynin Chloride ErOxybutynin Chloride103$2,631
Solifenacin Succinate44$2,428
Estradiol48$2,210
Trospium Chloride ErTrospium Chloride20$2,135
Alfuzosin Hcl ErAlfuzosin Hcl51$1,083
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip30$290
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst38$239
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim90$223
Dutasteride12$203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$467$285,606183 claims
Astellas Pharma US IncMyrbetriq$300$68,52176 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Downey

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →